Evaluation of Umeclidinium Bromide in Combination With Fluticasone Furoate in COPD Subjects With an Asthmatic Component
Status:
Completed
Trial end date:
2015-07-18
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the dose-response of 4 doses of umeclidinium bromide
in combination with fluticasone furoate compared with fluticasone furoate monotherapy in
chronic obstructive pulmonary disease participants with an asthmatic component. The
fluticasone furoate/umeclidinium bromide treatments will also be compared to the once-daily
inhaled corticosteroid/long-acting beta agonist combination fluticasone furoate/vilanterol.